Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | FBP1 | P09467 | 6/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484204 | 0.88 | PPARG (0.55) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL3484192 | 0.88 | PPARA (0.59) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL6091395 | 0.84 | PPARA (0.69) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL3484509 | 0.83 | PPARA (0.56) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL3483710 | 0.83 | PPARA (0.62) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL3900554 | 0.81 | PPARA (0.68) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL1549954 | 0.80 | PPARA (0.60) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL3484043 | 0.79 | PPARA (0.48) | PPARGPPARAFBP1ABCB11CYP1A2 | |
| SCHEMBL31538457 | 0.78 | MAOB (0.50) | PPARGPPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL3483913 | 0.77 | PPARA (0.62) | PPARGPPARAFBP1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | PPARG 422/4885PPARA 1045/4885FBP1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.